GI

Internet of Medical Things (IoMT) Market to reach over US$ 385.01 Bn by the year 2031 - Explained Details | Exclusive Study by InsightAce Analytic

Retrieved on: 
Wednesday, February 21, 2024
Cloud, Caregiver, Privacy, Artificial intelligence, IoMT, AI, SAP, Privacy by design, Medtronic, Risk, GI, GE HealthCare, Patient, Endoscopy, Siemens Healthineers, Internet, Partnership, Medical device

This strategic agreement strengthens Medtronic's leadership in AI-integrated healthcare products and marks a significant step in implementing AI into endoscopic treatment.

Key Points: 
  • This strategic agreement strengthens Medtronic's leadership in AI-integrated healthcare products and marks a significant step in implementing AI into endoscopic treatment.
  • In October 2023, SAP SE reported that Siemens Healthineers AG's digital transformation journey will be enabled by the RISE with SAP solution.
  • @ https://www.insightaceanalytic.com/enquiry-before-buying/1559
    Internet of Medical Things (IoMT) Market Dynamics:
    Despite the evident potential of the Internet of Medical Things (IoMT), the market faces significant restrictions primarily stemming from heightened Data Security and Privacy Concerns.
  • Despite the evident potential of the Internet of Medical Things (IoMT), the market faces significant restrictions primarily stemming from heightened Data Security and Privacy Concerns.

Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline

Retrieved on: 
Wednesday, February 14, 2024
Leptin, PD, Metabolism, Toxicity, Body composition, Ciprofloxacin, Clinical Pharmacokinetics, Water, LBW, Perfusion, LBM, Canadian International Council, AUC, PLOS One, Bariatric surgery, Clopidogrel, CYP, Breast, Health, DNA-binding protein, BMC Public Health, Pharmacology, BMI, CRP, Pharmaceutical Research (journal), Organ, Draft, Guideline, Bypass surgery, WHO, Ageing, INT, Pharmacokinetics, Liver, Bioavailability, Chronic liver disease, Human, Incidence, Committee, Absorption, TBW, Cardiovascular disease, Anatomy, CYP2C19, PBPK, Cmax, Factorization of polynomials, European, Lancet, CHMP, Journal, NASH, Pharmacotherapy, Adipose tissue, Non-alcoholic fatty liver disease, Journal of Clinical Investigation, Medication package insert, Overweight, NPS MedicineWise, Permeability, Benzodiazepine, Meta-analysis, Liver disease, Half-life, Acetylcholine, Ciclosporin, AAG, Kinetics, Midazolam, Kidney, Safety, Biomarker, Clinical Pharmacology & Therapeutics, Peptide, Classification, Hypertension, Metabolic syndrome, Acute coronary syndrome, Insulin resistance, Fatty liver disease, CYP2E1, Lithium, Body mass index, Reproduction, EMA, IBW, Injection, Anker, NCA, Enzyme, Inflammation, Cancer, Weight loss, Gastrointestinal tract, Cardiac output, Public health, Adipokine, CYP2C9, E pluribus unum, Physiology, Agency, Risk, Steroid, Lymph, CYP2D6, BSA, GI, Cytokine, Systematic review, Vaccine

Reflection paper on investigations of pharmacokinetics in

Key Points: 
    • Reflection paper on investigations of pharmacokinetics in
      the obese population
      Table of contents
      1.
    • References .............................................................................................. 9

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 2/12

      1.

    • This is considered
      a shortcoming that is potentially compounded by obese patients often being poorly represented in
      clinical studies.
    • The specific aims of this reflection paper are to:
      ?

      describe how the effects of obesity can be investigated during clinical medicinal product
      development.

    • ?

      provide recommendations on when investigations of the effect of obesity on the PK of a
      medicinal product should be particularly considered.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 3/12

      ?

      discuss how to reflect PK (and/or PK/PD) findings in weight/weight-based dosing
      recommendations.

    • Absorption
      Reduced rate of absorption linked to locally reduced blood flow (8) is reported for the subcutaneous
      and transdermal routes in obese subjects.
    • Distribution
      The distribution of medicinal products is driven by body composition, regional blood flow and binding to
      tissue and plasma proteins.
    • Obese subjects have a larger absolute lean body weight (LBW) as well as fat mass.
    • The physicochemical properties of a medicinal product (lipophilicity, polarity, molecular size, and
      degree of ionization) influence its distribution in the body.
    • In BMI class III obese
      subjects, the blood flow per gram of fat is significantly lower than that observed in class I obese or
      lean subjects (4).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 4/12

      An increased amount of alpha-1-acid-glycoprotein (AAG), linked to a chronic inflammatory state, is
      reported in obese individuals.

    • Fatty infiltrations are present in the liver for 90% of obese subjects, with the extent of the infiltrations
      being proportional to the degree of obesity.
    • In some cases, in particular for CYP3A4 metabolized medicinal products,
      bodyweight normalized clearance can be lower in obese patients (23).
    • Based on presently available data, it has been suggested that uptake transporters

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 5/12

      are downregulated while efflux transporters may be upregulated (31).

    • Platelet hyper-reactivity is also observed,
      which can impair the response to anti-platelet medicinal products in obese patients (42, 43).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 6/12

      3.

      the medicinal product properties and scientific literature indicate that obesity may lead to a
      marked effect on elimination and/or distribution or on the PK/PD relationship.

    • These
      models may aid in extrapolating the known efficacy and safety in the non-obese population to the
      obese population.
    • The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients
      Before and One Year After Bariatric Surgery.
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 11/12

      41.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 12/12

STARmed to Accelerate Global Market Entry of EUSRA and ELRA Products through Olympus

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, ELSA, ELRA, Hope, Standard of care, GI, Medtech, Patient, Pharmaceutical industry

EUSRA and ELRA products had been distributed by Taewoong Medical Co., Ltd., a Korean manufacturer of gastrointestinal medical devices.

Key Points: 
  • EUSRA and ELRA products had been distributed by Taewoong Medical Co., Ltd., a Korean manufacturer of gastrointestinal medical devices.
  • With the completion of Olympus' acquisition of Taewoong Medical, Olympus has become a global distribution partner of STARmed 's EUSRA and ELSA products.
  • This will enable STARmed to accelerate its global market expansion and provide better healthcare to patients around the world.
  • "We recognize STARmed's EUSRA and ELRA products as well-received and high-quality products," said Mike Callaghan, Vice President, General Manager of GI EndoTherapy at Olympus.

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

Retrieved on: 
Wednesday, February 14, 2024
Gastrointestinal cancer, Cancer, GEJ, Mink, Stomach, GI, Therapy, Paclitaxel, Patient, Disease, Tissue, Pharmaceutical industry

The trial builds upon findings from MiNK’s recently published clinical trial ( Carneiro et al .

Key Points: 
  • The trial builds upon findings from MiNK’s recently published clinical trial ( Carneiro et al .
  • 2024 Oncogene) demonstrating that agenT-797 appears to overcome resistance to immune checkpoint inhibitors, with durable disease stabilization and a confirmed response in chemotherapy and anti-PD-1 refractory gastric cancer.
  • "AgenT-797, an off-the-shelf iNKT cell-based therapy, has shown the capacity to target cancerous cells in diseased tissues and is compatible with immune checkpoint inhibitors.
  • This study builds upon the promising outcomes observed with iNKTs in gastric cancer and with botensilimab/balstilimab in GI cancers.

Fierce Healthcare Names Oshi Health a "Fierce 15" Company of 2024

Retrieved on: 
Monday, February 12, 2024
ACG, WTW, Investment, Growth, Digital, Data, Travel, Face, Health care, GI, American College, Creativity, Patient, American College of Gastroenterology, Modern Healthcare, Clinical trial, American Telemedicine Association, Diagnosis, Conditional sentence, BCBS, Partnership, Nursing

NEW YORK, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Oshi Health today announced that it has been named a "Fierce 15" company for 2024 by Fierce Healthcare. Oshi was recognized as one of the most innovative private healthcare companies looking to change the face of the industry by delivering effective, proven digestive care in a way that benefits patients, providers, health plans, and employers.

Key Points: 
  • Annual special report recognizes virtual specialty care innovator for transforming equity and access to care, achieving value-based health insurance contracts, and improving patient and provider experiences in digestive healthcare
    NEW YORK, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Oshi Health today announced that it has been named a "Fierce 15" company for 2024 by Fierce Healthcare.
  • "We are honored to be named a 'Fierce 15' innovator," said Sam Holliday, Oshi Health CEO.
  • Oshi was deemed a "Fierce" company for 2024 based on achievements in three core areas below, all core to Oshi's mission and values.
  • Read the 2024 Fierce 15 report: https://www.fiercehealthcare.com/special-reports/healthcare-conferences-...
    Earlier this month, Oshi Health was also named to the 2024 New York Digital Health 100 (DH100) for the third year, recognition by Digital Health New York (DHNY) that highlights the most exciting and innovative digital health startups in New York.

Previse Unveils New Headquarters and State-of-the Art Lab to Meet Growing Demand for Esopredict Test

Retrieved on: 
Thursday, February 8, 2024
DNA methylation, Growth, Heart, Health, Physician, GI, DNA, Risk, Patient, Research, CLIA

BALTIMORE, Feb. 8, 2024 /PRNewswire/ -- Previse, a company focused on improving health for patients with gastrointestinal diseases, today announced that it has relocated its headquarters and opened a new state-of-the-art CLIA high complexity laboratory in Baltimore, MD to meet demands for the company's first clinically available test, Esopredict.

Key Points: 
  • Esopredict, the first and only commercially available test that assesses DNA methylation levels to risk stratify patients with esophageal pre-cancer, analyzes epigenetic biomarkers to provide GI physicians and their patients personalized predictive data to guide patient treatments and endoscopic surveillance.
  • The expansion of Previse's CLIA lab increases its testing capacity to serve an additional 10,000 patients annually, which is a significant stride towards improving access to precise and expeditious diagnostic services.
  • Daniel Lunz, Co-founder and CEO, commented on the growth, "Our new headquarters and the expanded lab reflect our unwavering commitment to enhancing the value provided to physicians and patients, which is at the heart of our innovation-driven ethos."
  • The move will also expand the research capabilities of Previse, as the company develops additional innovative technologies including minimally invasive tests for upper GI disease detection and monitoring and to further service ongoing research partnerships.

VetComm Urges Action: The Unsettling Impact of Free College on Military Recruitment Threatens National Security

Retrieved on: 
Thursday, February 8, 2024
Attention, College, Space force, Congress, Army, Legislation, Spirit, GI, University, Air force, Private sector, DOD, Education, Pentagon, Navy, G.I. Bill, Veteran, Service, Organization

SAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- As the United States grapples with a historic recruiting crisis within the military, VetComm, a leading advocate for veterans' rights, is drawing attention to the adverse effects of calls for free college on recruitment. The decline in military enlistment, particularly in the Army, Navy and Air Force, poses a significant threat to national security and demands a reevaluation of policies surrounding education incentives for service members. As such, VetComm is highlighting the urgent need for comprehensive solutions to address this concerning trend.

Key Points: 
  • The decline in military recruitment is represented most acutely in Gen Z, which has a low trust in institutions.
  • "In our nation's past, veterans were rewarded with benefits like free college education, a gesture of gratitude for their honorable service.
  • Today, the push for universal free college is inadvertently undermining the very foundation that once attracted individuals to military service," explained Monroe.
  • However, external policies advocating for free college have only worsened the Department of Defense's challenges, with discussions of conscription resurfacing.

Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Collaboration, Regurgitation, GI, IND, Patient, Gastroparesis, FDA, Food, D2, PPI, Gastroesophageal reflux disease, FACC, Disease, Heartburn, GERD, Pharmaceutical industry

Falk Pharma”), has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) as the second indication in their licensed territories.

Key Points: 
  • Falk Pharma”), has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease (PPI-nrsGERD) as the second indication in their licensed territories.
  • In October 2021, Renexxion and Dr. Falk Pharma announced an exclusive Licensing and Collaboration Agreement to advance naronapride initially for gastroparesis in Greater Europe (including UK), Russia, Central Asian Republics, and certain Australasian countries.
  • Today, Renexxion is pleased to confirm that Dr. Falk Pharma will also advance naronapride for PPI-non-responsive symptomatic GERD in these regions.
  • This is a welcomed addition to our pipeline which includes naronapride for gastroparesis.”
    “We are very pleased that our European partner, Dr. Falk Pharma, chose PPI-nrsGERD as its next indication for development for naronapride in their territories.

Vivante Health Named to the New York Digital Health 100 By Digital Health New York (DHNY)

Retrieved on: 
Tuesday, February 6, 2024
Digital health, Life, GI, Digital, Work, IBS, Health, Heartburn

CHICAGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, today announced that it was named to the 2024 New York Digital Health 100 (DH100), a recognition that highlights the leading digital health startups in New York.

Key Points: 
  • CHICAGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, today announced that it was named to the 2024 New York Digital Health 100 (DH100), a recognition that highlights the leading digital health startups in New York.
  • Digital Health New York (DHNY) publishes the annual list in conjunction with the New York Healthcare Innovation Report which takes an in-depth look at the investment trends, opportunities, and challenges in the digital health sector.
  • “Millions of workers across the country struggle with debilitating GI symptoms and issues that interfere with their life and work,” said Bill Snyder, CEO of Vivante Health.
  • The company has raised $47 million in total funding , and GIThrive recently became the first digestive health offering selected for Cigna’s Evernorth Digital Health Formulary .

Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd

Retrieved on: 
Wednesday, January 24, 2024
Knowledge, Comment, GI, Duodenum, Patient, Esophagus, Stenosis, Name, Medtech, Gastrointestinal disease, Acquisition, Sale, Health, Biliary tract, Pharmaceutical industry

[2]

Key Points: 
  • [2]
    Taewoong Medical offers a variety of medical devices including metallic stents designed for biliary tract, esophagus, colon, and duodenum treatments.
  • Taewoong Medical will join Olympus' Therapeutic Solutions Division, helping Olympus become a comprehensive solutions provider in the GI market with varied GI EndoTherapy solutions by bringing together talent and technology.
  • The addition of Taewoong Medical to Olympus' portfolio will contribute to the company's focus on enhancing patient care pathways.
  • Comment from Kyong-min Shin, President and CEO of Taewoong Medical: "As a leading medical company, Taewoong Medical manufactures a vast range of medical equipment of our own designs.